TSC-101 is under clinical development by TScan Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TSC-101 overview

TSC-101 is under development for the treatment of blood cancers like acute myelocytic Leukemia, acute lymphocytic leukemia and myelodysplastic syndrome. The therapeutic candidate comprises of autologous T cells engineered to express a T-cell receptor (TCR) that targets HA-2 antigen. The drug candidate is developed based on the TScan platform technology. It is administered by intravenous route.

TScan Therapeutics overview

TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.

For a complete picture of TSC-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.